It is not a matter of editorial opinion to say these words: Black Lives Matter.
As the leading independent source of news in oncology, The Cancer Letter has decided that it is our moral imperative to provide coverage of COVID-19 free of charge until this crisis is resolved.
You are looking at The Cancer Letter's summer issue, a collection of stories we have compiled for you as we (and, we hope, you) go off on a brief summer recess.
This year, we decided to approach the annual meeting of the American Society of Clinical Oncology in a completely new way: through illustrations.
Our investigative story this week is an outgrowth of a correction.
The moonshot, The Cancer Letter's biggest area of coverage of 2016, continues into 2017.
As the New Year approaches, we are preparing to revamp our website and launch an app. The work on it is almost done—a January launch seems likely.
A federal judge ruled that Amgen Inc. cannot force me to answer questions related to a 2007 story that sparked a class action suit by investors and triggered a change in FDA regulations of erythropoiesis-stimulating agents.
2014 was a transformative year for The Cancer Letter.
